Company profile
ALUMIS INC.
NASDAQ:ALMSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ENVUDEUCITINIB | phase3 | — | 10 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06588738 | phase3 | completed | 2024-08-20 | 2025-09-23 | Alumis Inc | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
| NCT06586112 | phase3 | completed | 2024-07-25 | 2025-09-19 | Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
| NCT05600036 | phase2 | completed | 2022-09-27 | 2023-06-29 | Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis |
| NCT06952634 | phase1 | completed | 2025-04-29 | 2026-03-24 | Alumis Inc | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage |
| NCT06962774 | phase1 | completed | 2025-04-23 | 2025-08-01 | Alumis Inc | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function |
FDA applications (0)
No records yet.